Hemcheck Sweden AB and Capio S:t Göran’s Hospital have received approval from the Swedish Ethical Review Authority (EPN) to perform a study at Capio S:t Göran’s hospital emergency care unit to evaluate if Hemcheck’s product concept can lower the hemolysis rate in hemolysis sensitive blood samples sent to the central laboratory at Capio S:t Göran’s hospital.

The study is designed so that one part of the staff will use Hemcheck’s equipment for a limited time and then the result is compared against a control group where the equipment is not used.

– We look forward to this study where we hope we can show to Capio S:t Göran’s Hospital that our solution for point of care hemolysis detection can streamline blood sampling and greatly contribute to reducing the hemolysis rate in blood samples, and thus, among other things, can increase patient safety and quality of care. Together with Capio S:t Göran’s Hospital, we have chosen to seek EPN’s approval for this study in order to be able to collect more information than usual linked to the blood sampling and more easily follow up samples screened with our equipment, says Joen Averstad, CEO of Hemcheck.

“We are a forward-looking organization that constantly want to develop ourselves. As we see a problem with hemolysis in blood samples, we look forward to this study to build more knowledge about how we can handle the problem in a new way and to evaluate whether Hemcheck’s solution may be something we want to implement, says Göran Örnung, Head of the emergency medicine clinic at Capio S:t Göran’s Hospital.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 076 108 8191

E-post: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399 info@fnca, is a Certified Adviser to the company.

About Capio S:t Göran’s Hospital

Capio S:t Göran’s Hospital is an emergency hospital for adult patients, located at Kungsholmen in Stockholm. The hospital is Stockholm’s most centrally located emergency hospital and one of the country’s largest in terms of the number of emergency patients. In 2018, approximately 100,000 visits were done at the emergency care unit. Capio S:t Göran’s Hospital is part of Capio, which in turn is part of Ramsay Générale de Santé, a leading European healthcare provider operating 235 hospitals around the world.